Author: Michaud, Neil R

Source: Expert Opinion on Therapeutic Patents, Volume 15, Number 5, 1 May 2005 , pp. 621-625(5)

Publisher: Informa Healthcare

Abstract:

Dysregulated growth factor signalling is an important hallmark of cancer. The receptor tyrosine kinase c-Met has been implicated in the development of many carcinomas and sarcomas, and multiple therapeutic approaches to target the hepatocyte growth factor (HGF)/c-Met signalling axis are being pursued by several companies. Here, monomeric peptides or chemically-conjugated multimeric polypeptides that antagonise binding of HGF to c-Met and abrogate c-Met function are claimed as a treatment for cancer.

Keywords: cancer; c-Met; hepatocyte growth factor (HGF); kinase inhibitor; peptide antagonist; therapeutic monoclonal antibody; tumour

Document Type: Miscellaneous

DOI: http://dx.doi.org/10.1517/13543776.15.5.621

Publication date: 2005-05-01

More about this publication?

• Editorial Board
• Information for Authors
• Subscribe to this Title
• Terms & Conditions
• ingentaconnect is not responsible for the content or availability of external websites

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Michaud, Neil R

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers